Webcast on Friday, September 26, 2014 at 8:30 a.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage emerging
pharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol
(LDL-cholesterol) lowering therapies for the treatment of
hypercholesterolemia and other cardiometabolic risk markers, today
announced the Company will present at the BioCentury NewsMakers in the
Biotech Industry Conference in New York City, N.Y. The presentation will
take place on Friday, September 26 at 8:30 a.m. Eastern Time, when Tim
M. Mayleben, president and chief executive officer, will provide an
update on the company.
A live, listen-only webcast of the presentation can be accessed on the
investor relations section of the Esperion website at www.esperion.com.
A webcast replay of the presentation will be available approximately one
hour after completion and will be archived on the Company's website for
90 days following the event.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with
cardiometabolic diseases. The Esperion team leverages its understanding
of, and experience with, key biological pathways to discover and develop
innovative therapies for the treatment of patients with
hypercholesterolemia who have uncontrolled cholesterol levels despite
the use of currently available therapies. Esperion has assembled a
portfolio of programs including one product candidate in late-stage
clinical evaluation (ETC-1002) and two pre-clinical product candidates.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical-stage emerging pharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed
primarily for patients with hypercholesterolemia and a history of statin
intolerance. Phase 2b clinical trials for ETC-1002 are currently
underway and build upon the successful and comprehensive Phase 1 and
Phase 2a programs. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
Westwicke Partners
Jordan Kohnstam, 443.450.4189
jordan.kohnstam@westwicke.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media